Idera Pharmaceuticals Inc.

0.4100+0.0566+16.02%Vol 45.40M1Y Perf -66.34%
May 17th, 2022 16:00 DELAYED
BID0.4060 ASK0.4100
Open0.5383 Previous Close0.3534
Pre-Market- After-Market0.43
 - -  0.02 4.88%
Target Price
2.00 
Analyst Rating
— 0.00
Potential %
387.81 
Finscreener Ranking
★★★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★+     54.19
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★+     49.58
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.13 
Earnings Rating
Neutral
Market Cap21.72M 
Earnings Date
5th May 2022
Alpha-0.04 Standard Deviation0.26
Beta1.54 

Today's Price Range

0.40230.5589

52W Range

0.29501.71

5 Year PE Ratio Range

-4.30-1.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
28.61%
1 Month
-4.70%
3 Months
-15.78%
6 Months
-41.43%
1 Year
-66.34%
3 Years
-83.79%
5 Years
-97.09%
10 Years
-95.02%

TickerPriceChg.Chg.%
IDRA0.41000.056616.02
AAPL149.243.70002.54
GOOG2 334.0338.18001.66
MSFT266.825.32002.03
XOM92.111.16001.28
WFC43.711.50003.55
JNJ178.820.74000.42
FB202.622.58001.29
GE76.401.77002.37
JPM122.183.92003.31
Financial StrengthValueIndustryS&P 500US Markets
7.40
7.70
0.02
0.03
-5 455.30
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-4 034.70
-4 027.10
-4 880.70
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-40.82
35.11
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.08-
Q04 2021--0.08-
Q03 2021--0.11-
Q02 2021-0.21-0.1528.57
Q01 2021-0.21-0.1433.33
Q04 2020-0.23-0.218.70
Q03 2020-0.21-0.22-4.76
Q02 2020-0.36-0.2627.78
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.23-9.52Negative
12/2021 QR-0.175.56Positive
12/2021 FY-0.82-1.23Negative
12/2022 FY-0.5018.03Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume45.40M
Shares Outstanding52.97K
Shares Float41.11M
Trades Count51.37K
Dollar Volume22.49M
Avg. Volume177.87K
Avg. Weekly Volume191.92K
Avg. Monthly Volume169.94K
Avg. Quarterly Volume171.76K

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) stock closed at 0.41 per share at the end of the most recent trading day (a 16.02% change compared to the prior day closing price) with a volume of 45.40M shares and market capitalization of 21.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Idera Pharmaceuticals Inc. CEO is Vincent J. Milano.

The one-year performance of Idera Pharmaceuticals Inc. stock is -66.34%, while year-to-date (YTD) performance is -28.07%. IDRA stock has a five-year performance of -97.09%. Its 52-week range is between 0.295 and 1.71, which gives IDRA stock a 52-week price range ratio of 8.13%

Idera Pharmaceuticals Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 0.72, a price-to-sale (PS) ratio of 41.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.64%, a ROC of -48.30% and a ROE of -51.20%. The company’s profit margin is -%, its EBITDA margin is -4 027.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Idera Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Idera Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Idera Pharmaceuticals Inc. is (0), with a target price of $2, which is +387.81% compared to the current price. The earnings rating for Idera Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Idera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Idera Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.14, ATR14 : 0.06, CCI20 : 63.36, Chaikin Money Flow : -0.87, MACD : -0.03, Money Flow Index : 97.75, ROC : -5.09, RSI : 47.26, STOCH (14,3) : 43.58, STOCH RSI : 1.00, UO : 33.24, Williams %R : -56.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Idera Pharmaceuticals Inc. in the last 12-months were: Daniel B. Soland (Buy at a value of $59 500)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Hold
3.00

Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates.

CEO: Vincent J. Milano

Telephone: +1 484 348-1600

Address: 505 Eagleview Boulevard, Exton 19341, PA, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

61%39%

News

Stocktwits